Spermidine for Aging

Verdict: Weak, unproven for slowing aging

Despite a plausible mechanism (autophagy induction), spermidine has not been shown to slow human aging: the largest, highest-quality trial missed its primary endpoint, and no human studies test lifespan or healthspan. The grade is Weak (Tier C).

C 🟠 C Weak Evidence Taiwan Regulatory Restriction

🔬Why this grade7-layer evidence engine

The human evidence rests on four small RCTs and points more negative than positive. The largest and best-conducted trial (SmartAge, PMID 35616942; n=100, 52 weeks) found no benefit on its primary memory endpoint (treatment effect -0.03, p=0.47); only an exploratory inflammatory marker moved in a high-compliance subgroup. A smaller 12-week pilot (PMID 30388439; n=30) reported a memory gain (Cohen's d=0.79), but it is underpowered and was contradicted by the larger study. A safety trial (PMID 29315079) showed good tolerability but did not test efficacy.

A key mechanistic problem undercuts the whole case: a pharmacokinetic RCT (PMID 37111071; n=12) found that 15 mg/day of oral spermidine did not raise plasma or salivary spermidine, challenging the assumption that supplements reach the levels animal studies rely on. Critically, no human RCT has ever measured lifespan or healthspan; longevity claims rest only on dietary-intake epidemiology.

Regulators and clinicians reinforce the caution. The US FDA 'ceased to evaluate' the GRAS notice at the maker's request, EFSA's 6 mg/day limit is a food-safety ceiling (wheat-germ extract only) with no approved health claims, and Health Canada bars its use in natural health products without more safety data. The American Federation for Aging Research is blunt: 'There are no proven anti-aging interventions,' and Mayo, Cleveland Clinic and Harvard Health say nothing at all. Together this supports a Weak (Tier C) grade, not an endorsement.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.48
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Taiwan Regulatory Restriction
Confidence
77%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.485
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline (SmartAge)
PMID: 35616942 2022 RCT (double-blind) n = 100
Finding: No significant benefit on memory; adjusted treatment effect -0.03 (95% CI -0.11 to 0.05; p=0.47). Exploratory sICAM-1 reduction (p=0.03) in high-compliance subgroup only.
🟢 High quality Mixed funding Effect size: MD -0.03 (95% CI -0.11 to 0.05)
View on PubMed
The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial
PMID: 30388439 2018 RCT (double-blind) n = 30
Finding: Moderate improvement in mnemonic discrimination in spermidine group vs placebo; Cohen's d=0.79 (p not explicitly stated; CI trending p<0.05).
Academic Effect size: Cohen's d 0.79 (mnemonic discrimination); d 0.77 (overall memory)
View on PubMed
High-Dose Spermidine Supplementation Does Not Increase Spermidine Levels in Blood Plasma and Saliva of Healthy Adults
PMID: 37111071 2023 RCT (double-blind) n = 12
Finding: Spermidine supplementation did NOT raise plasma or salivary spermidine vs placebo; only plasma spermine modestly increased. Challenges bioavailability/PK assumption for oral spermidine.
View on PubMed
Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline
PMID: 29315079 2018 RCT (double-blind) n = 30
Finding: No safety signal vs placebo; compliance >85%. Established tolerability but not efficacy.
Government
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Neutral
At the notifier's request, FDA ceased to evaluate this notice source↗
L4b EU EFSA
Cautious
Equivalent of max. 6 mg/day spermidine; Food supplements as defined in Directive 2002/46/EC, excluding food supplements for infants, young children, children, adolescents, pregnant and lactating women. The designation of the novel food on the labelling of the foodstuffs containing it shall be 'spermidine-rich wheat germ extract'. source↗
L4e WHO
Cautious
Spermidine [in Spermidine trihydrochloride] ... This ingredient cannot be used in natural health products without the submission of additional evidence for safety. source↗
L5e Specialty Society (condition-mapped)
Not addressed
There are no proven anti-aging interventions source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-aging-INT-spermidine-001 繁體中文版 →